Melanoma and Other Skin Cancers

Share

Program Content

Activities

  • Conference to Clinic Melanoma
    Conference to Clinic: Melanoma and Other Skin Cancers
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2023

  • Conference to Clinic: Melanoma and Other Skin Cancers
    Conference to Clinic: Expert Analysis of the Top Melanoma and Other Skin Cancers Abstracts From the 2023 Oncology Meeting in Chicago
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 29, 2023

    Expires: June 28, 2024

  • ASCO 2023: Key Melanoma Studies
    Key Studies in Skin Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 21, 2023

    Expires: August 20, 2024

Activities

OpACIN-neo and PRADO
OpACIN-neo and PRADO: Effect of Response-Directed Treatment Personalization on Survival After Neoadjuvant Immune Checkpoint Blockade in Stage III Melanoma
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

RELATIVITY-047 2-Yr Update
RELATIVITY-047: 2-Yr Update of First-line Nivolumab + Relatlimab vs Nivolumab in Advanced Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

KEYNOTE-716: DMFS and RFS Update
Phase III KEYNOTE-716 Update: Final DMFS Analysis of Adjuvant Pembrolizumab vs Placebo in Stage IIB/IIC Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

Fianlimab/Cemiplimab in Adv Melanoma
Phase I Trial of Fianlimab (Anti‒LAG-3 mAb) + Cemiplimab (Anti‒PD-1 mAb) in Patients With Advanced Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

Adjuvant mRNA-4157 + Pembro in Melanoma
Phase II KEYNOTE-942: DMFS With Adjuvant mRNA-4157 (V940) + Pembrolizumab vs Pembrolizumab in Resected High-Risk Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

CheckMate 76K: Biomarker Analysis
Biomarker Analysis From CheckMate 76K Phase III Trial of Adjuvant Nivolumab vs Placebo in High-Risk Stage IIB/C Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc